Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

A 2020 vision of ocular gene therapy

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Rodriguez-Estevez L, Asokan P, Borrás T, Transduction optimization of AAV vectors for human gene therapy of glaucoma and their reversed cell entry characteristics. Gene Ther. 2019. https://doi.org/10.1038/s41434-019-0105-4.

  2. Borrás T, Buie LK, Spiga MG. Inducible scAAV2.GRE.MMP1 lowers IOP long-term in a large animal model for steroid-induced glaucoma gene therapy. Gene Ther. 2016;23:438–49. https://doi.org/10.1038/gt.2016.14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Song L, Llanga T, Conatser LM, Zaric V, Gilger BC, Hirsch ML. Serotype survey of AAV gene delivery via subconjunctival injection in mice. Gene Ther. 2018;25:402–14. https://doi.org/10.1038/s41434-018-0035-6.

    Article  CAS  PubMed  Google Scholar 

  4. Nascimento-Dos-Santos G, Teixeira-Pinheiro LC, da Silva-Júnior AJ, Carvalho LRP, Mesentier-Louro LA, Hauswirth WW, et al. Effects of a combinatorial treatment with gene and cell therapy on retinal ganglion cell survival and axonal outgrowth after optic nerve injury. Gene Ther. 2019. https://doi.org/10.1038/s41434-019-0089-0.

  5. Cao X, Yung J, Mak H, Leung CKS. Factors governing the transduction efficiency of adeno-associated virus in the retinal ganglion cells following intravitreal injection. Gene Ther. 2019;26:109–20. https://doi.org/10.1038/s41434-019-0060-0.

    Article  CAS  PubMed  Google Scholar 

  6. Dias MS, Araujo VG, Vasconcelos T, Li Q, Hauswirth WW, Linden R, et al. Retina transduction by rAAV2 after intravitreal injection: comparison between mouse and rat. Gene Ther. 2019;26:479–90. https://doi.org/10.1038/s41434-019-0100-9.

    Article  CAS  PubMed  Google Scholar 

  7. Zeng Y, Qian H, Wu Z, Marangoni D, Sieving PA, Bush RA. AAVrh-10 transduces outer retinal cells in rodents and rabbits following intravitreal administration. Gene Ther. 2019;26:386–98. https://doi.org/10.1038/s41434-019-0094-3.

    Article  CAS  PubMed  Google Scholar 

  8. Sullivan JA, Stanek LM, Lukason MJ, Bu J, Osmond SR, Barry EA, et al. Rationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brain. Gene Ther. 2018;25:205–19. https://doi.org/10.1038/s41434-018-0017-8.

    Article  CAS  PubMed  Google Scholar 

  9. Boyd RF, Boye SL, Conlon TJ, Erger KE, Sledge DG, Langohr IM, et al. Reduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogs. Gene Ther. 2016;23:548–56. https://doi.org/10.1038/gt.2016.31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Georgiadis A, Duran Y, Ribeiro J, Abelleira-Hervas L, Robbie SJ, Sünkel-Laing B, et al. Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65. Gene Ther. 2016;23:857–62. https://doi.org/10.1038/gt.2016.66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Kampik D, Basche M, Luhmann UFO, Nishiguchi KM, Williams JAE, Greenwood J, et al. In situ regeneration of retinal pigment epithelium by gene transfer of E2F2: a potential strategy for treatment of macular degenerations. Gene Ther. 2017;24:810–8. https://doi.org/10.1038/gt.2017.89.

    Article  CAS  PubMed  Google Scholar 

  12. Hickey DG, Edwards TL, Barnard AR, Singh MS, de Silva SR, McClements ME, et al. Tropism of engineered and evolved recombinant AAV serotypes in the rd1 mouse and ex vivo primate retina. Gene Ther. 2017;24:787–800. https://doi.org/10.1038/gt.2017.85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. De Silva SR, Charbel Issa P, Singh MS, Lipinski DM, Barnea-Cramer AO, Walker NJ, et al. Single residue AAV capsid mutation improves transduction of photoreceptors in the Abca4-/- mouse and bipolar cells in the rd1 mouse and human retina ex vivo. Gene Ther. 2016;23:767–74. https://doi.org/10.1038/gt.2016.54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Lu Q, Ganjawala TH, Ivanova E, Cheng JG, Troilo D, Pan ZH. AAV-mediated transduction and targeting of retinal bipolar cells with improved mGluR6 promoters in rodents and primates. Gene Ther. 2016;23:680–9. https://doi.org/10.1038/gt.2016.42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Sugano E, Tabata K, Takahashi M, Nishiyama F, Shimizu H, Sato M, et al. Local and systemic responses following intravitreous injection of AAV2-encoded modified Volvox channelrhodopsin-1 in a genetically blind rat model. Gene Ther. 2016;23:158–66. https://doi.org/10.1038/gt.2015.99.

    Article  CAS  PubMed  Google Scholar 

  16. Ameline B, Tshilenge KT, Weber M, Biget M, Libeau L, Caplette R, et al. Long-term expression of melanopsin and channelrhodopsin causes no gross alterations in the dystrophic dog retina. Gene Ther. 2017;24:735–41. https://doi.org/10.1038/gt.2017.63.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This study was supported by NIHR Oxford Biomedical Research Centre.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Robert E. MacLaren.

Ethics declarations

Conflict of interest

The author is a named inventor on several retinal gene therapy patents owned by the University of Oxford. He is or has recently been a consultant in relation to retinal gene therapy to Novartis, Biogen, Spark Therapeutics, Gyroscope Therapeutics and the National Institute for Health and Care Excellence, which advises the UK National Health Service.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

MacLaren, R.E. A 2020 vision of ocular gene therapy. Gene Ther 28, 217–219 (2021). https://doi.org/10.1038/s41434-020-0170-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41434-020-0170-8

Search

Quick links